Arialys Therapeutics
A biotechnology company pioneering new therapeutics for autoimmune neuropsychiatry.
The Californian company is developing new precision medicines to specifically block pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease.
Arialys' lead therapeutic candidate, ART5803, is being developed as a potential treatment for anti-NMDA receptor encephalitis, a life-threatening neurological disease that causes severe psychosis. ART5803 also has potential to treat autoimmune dementia.
Latest Arialys Therapeutics News & Features
28 June 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze